Association of non-HDL cholesterol with subclinical atherosclerosis in HIV-positive patients

J Infect. 2008 Jul;57(1):47-54. doi: 10.1016/j.jinf.2008.05.007. Epub 2008 Jun 12.

Abstract

Objectives: To assess the relationship between non-classical cardiovascular (CV) risk factors including non-HDL cholesterol (non-HDL-C), apolipoprotein B, triglycerides to HDL ratio, LDL size, inflammation or oxidative stress parameters and carotid intima-media thickness (CIMT), in order to better identify prevention or therapeutic targets. In addition, we studied the relationship between metabolic syndrome (MS) and CIMT.

Methods: Cross-sectional study including 232 HIV-positive (HIV+) adults (80% treated by combined antiretroviral therapy) extracted from the ANRS CO3 Aquitaine Cohort.

Results: There was a significant association of higher non-HDL-C (p<0.01), apolipoprotein B (p<0.01) levels or TG/HDL ratio (p<0.05) with higher CIMT when compared the first vs fourth quartile, while there is no association between CIMT and LDL-C (p=0.09) or LDL size (p=0.55). In multivariate analysis, only the TG/HDL molar ratio > 1.5 tend toward significance (p=0.08). MS was observed in only 7.3% of patients with the NCEP-ATP III definition and 11.2% with the IDF criteria. Whatever the used definition, there was a significant association between MS presence and increased CIMT (p<0.05) in univariate and multivariate model.

Conclusions: Non-HDL-C, TG/HDL ratio and apolipoprotein B levels, which are closely linked to lipid disorders associated to the MS, appear as stronger predictive markers than LDL-C for screening subclinical atherosclerosis in HIV+ populations. Achieving non-HDL-C target defined by the NCEP-ATP III guidelines appears of great importance to reduce CV complications in HIV+ patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Apolipoproteins B / blood
  • Atherosclerosis / epidemiology*
  • Atherosclerosis / etiology*
  • Atherosclerosis / physiopathology
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / physiopathology
  • Cholesterol / blood*
  • Cholesterol, HDL / blood
  • Drug Therapy, Combination
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Male
  • Metabolic Syndrome / epidemiology
  • Metabolic Syndrome / etiology
  • Middle Aged
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Risk Factors
  • Triglycerides / blood

Substances

  • Anti-HIV Agents
  • Apolipoproteins B
  • Cholesterol, HDL
  • Reverse Transcriptase Inhibitors
  • Triglycerides
  • Cholesterol